GlobeNewswire·Oct 23, 2026, 1:01 PM ET

NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue

NTHI

NeOnc Technologies Holdings (NASDAQ: NTHI) cleared resistance levels above $3 with strong trading volume, signaling a potential technical reversal after testing lows near $2.50.
The stock reclaimed its 9-day exponential moving average near $2.79, moved above the VWAP around $2.87, and showed an improving daily MACD histogram.
Next technical resistance areas to watch are $3.30–$3.40 and $3.50, where previous activity and the declining 50-day EMA are located.
Reported short interest increased by approximately 45.1% from 522,311 shares on September 15 to 757,739 shares on September 30.
NeOnc is scheduled to appear on "Health Uncensored with Dr. Drew" on Fox Business Network on Sunday, October 25, at 5:30 p.m. ET.
On October 21, the company announced a Memorandum of Understanding (MOU) with the Department of Health–Abu Dhabi covering scientific exchange, specialist training, & clinical research opportunities.
Two children in Abu Dhabi are currently receiving investigational NEO100 via the Compassionate Care program, with a third patient expected to join.
An early clinical observation noted a critically ill three-year-old boy treated with NEO100 was breathing independently without a ventilator & began moving his legs.
Published analyst price targets for NTHI include $13 from Alliance Global Partners, $15 from BTIG, & $20 each from Maxim & Roth Capital, averaging $17.
This report is a paid editorial by 24/7 Market News intended for informational purposes only & does not constitute financial or investment advice.
The release contains forward-looking statements subject to risks & uncertainties, with actual results potentially differing materially from those described.